Jim Birchenough
Stock Analyst at Wells Fargo
(2.66)
# 2,092
Out of 4,944 analysts
36
Total ratings
45%
Success rate
23.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Equal-Weight | $3 → $2 | $0.54 | +270.64% | 2 | Dec 31, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $57.33 | +22.10% | 3 | Feb 22, 2024 | |
| MEIP MEI Pharma | Downgrades: Equal-Weight | $260 → $40 | $5.14 | +678.21% | 4 | Mar 25, 2022 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $13.94 | +244.33% | 3 | Feb 9, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $6 → $7 | $0.08 | +8,851.41% | 2 | Sep 22, 2021 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $1.13 | +11,404.42% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $1.91 | +632.98% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $26.89 | +439.23% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $120.14 | -47.56% | 5 | Oct 29, 2020 | |
| RNA Avidity Biosciences | Initiates: Overweight | n/a | $46.15 | - | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 | $14.60 | +283.56% | 3 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $734 | $561.55 | +30.71% | 2 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $180 | $3.92 | +4,491.84% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $6.00 | +450.00% | 3 | Jun 28, 2018 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.54
Upside: +270.64%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $57.33
Upside: +22.10%
MEI Pharma
Mar 25, 2022
Downgrades: Equal-Weight
Price Target: $260 → $40
Current: $5.14
Upside: +678.21%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $13.94
Upside: +244.33%
Adaptimmune Therapeutics
Sep 22, 2021
Maintains: Equal-Weight
Price Target: $6 → $7
Current: $0.08
Upside: +8,851.41%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $1.13
Upside: +11,404.42%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $1.91
Upside: +632.98%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $26.89
Upside: +439.23%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $120.14
Upside: -47.56%
Avidity Biosciences
Jul 7, 2020
Initiates: Overweight
Price Target: n/a
Current: $46.15
Upside: -
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $14.60
Upside: +283.56%
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $561.55
Upside: +30.71%
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $3.92
Upside: +4,491.84%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $6.00
Upside: +450.00%